Takeda is expected to post a 92% drop in net profit from a year earlier to 15.96 billion yen ($122.3 million) for the quarter ended March 31, according to a poll of analysts by S&P Global Market Intelligence.

That’s compared with a net profit of Y197.1 billion a year earlier, which was boosted by gains from the sale of its consumer healthcare business.

According to the poll by S&P Global Market Intelligence, revenue is estimated to have risen 10% from a year earlier to Y848.14 billion, according to the poll by S&P Global Market Intelligence.

Takeda’s third-quarter revenue was boosted by sales of several products such as ulcerative colitis drug Entyvio and Vyvanse, a drug for attention-deficit hyperactivity disorder. Investors will focus on sales of these key drugs.

Higher costs of sales and research and development expenses weighed on Takeda’s margins in its third quarter. Operating-profit margin declined to 12.9% from 17.1% a year earlier. Investors will pay attention to margin trends.

Takeda is expected to give earnings projections for the new fiscal year that started in April and also the company is scheduled to report its fourth-quarter results on Wednesday. Investors will pay attention to management’s revenue and profit forecasts.